SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $12.00.

Several analysts have recently weighed in on SABS shares. Weiss Ratings upgraded SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Wall Street Zen raised SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Perceptive Advisors LLC raised its holdings in SAB Biotherapeutics by 700.8% during the first quarter. Perceptive Advisors LLC now owns 6,431,743 shares of the company’s stock worth $24,634,000 after purchasing an additional 5,628,533 shares in the last quarter. Affinity Asset Advisors LLC bought a new position in SAB Biotherapeutics during the 1st quarter valued at $2,202,000. Monashee Investment Management LLC bought a new position in SAB Biotherapeutics during the 1st quarter valued at $1,915,000. Seven Fleet Capital Management LP acquired a new position in shares of SAB Biotherapeutics during the 1st quarter valued at $1,915,000. Finally, DV Trading LLC acquired a new position in shares of SAB Biotherapeutics during the 1st quarter valued at $1,532,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock opened at $3.23 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.22 and a current ratio of 9.22. SAB Biotherapeutics has a 12 month low of $2.44 and a 12 month high of $5.15. The stock’s 50-day moving average is $3.27 and its 200-day moving average is $3.69.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). Equities research analysts anticipate that SAB Biotherapeutics will post -1.17 earnings per share for the current year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.